News
-
-
PRESS RELEASE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase® Technologies Inc. announces the addition of Dr. Michael Jewett as an independent consultant to assist in completing enrollment of patients in the Phase II NMIBC CIS clinical study. Dr. Jewett's expertise will help achieve regulatory approval -
PRESS RELEASE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Theralase Technologies Inc. has closed a non-brokered private placement offering of units, raising approximately $CAN 1,200,000 for cancer research and development. The company plans to use the funds for clinical study, preclinical research, and general corporate purposes -
PRESS RELEASE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, demonstrating favorable interim clinical data that exceeds the International Bladder Cancer Group's guidelines. With 63 patients treated to date, the study shows promising results, potentially leading to Break Through Designation and Accelerated Approval. The Company plans to complete enrollment and delivery of the primary Study II Treatment for all patients in 2024, with potential Health Canada and FDA approval expected by 2026 / 2027. -
-
-
-
PRESS RELEASE
Theralase(R) Announces Brokered LIFE Financing
-
-
